Ten who did not receive such therapy (median IGRA value, 0.42 IU/mL; range 0.35–10 IU/mL) repeated the IGRA test 1 to 6 months later, and 8 of them had negative results.
Clinical Trials Arena on MSN16d
IAVI and Biofabri dose first adults and teens in TB vaccine trialIAVI and Biofabri are collaborating on the trial, which will recruit around 4,300 patients with latent TB infections across four countries.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback